Cargando…
Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
BACKGROUND: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a promising approach for lymphomas. This study aimed to evaluate the effect of ifosfamide, cisplatin or carboplatin, and etoposide (ICE)-based regimen as a mobilization regimen on relapsed, refractory, or h...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725560/ https://www.ncbi.nlm.nih.gov/pubmed/26365969 http://dx.doi.org/10.4103/0366-6999.164936 |
_version_ | 1782411648493944832 |
---|---|
author | Zhou, Ping Liu, Peng Zhou, Sheng-Yu He, Xiao-Hui Han, Xiao-Hong Qin, Yan Yang, Sheng Zhang, Chang-Gong Gui, Lin Yao, Jia-Rui Zhao, Li-Ya Zhang, Shu-Xiang Sun, Yan Shi, Yuan-Kai |
author_facet | Zhou, Ping Liu, Peng Zhou, Sheng-Yu He, Xiao-Hui Han, Xiao-Hong Qin, Yan Yang, Sheng Zhang, Chang-Gong Gui, Lin Yao, Jia-Rui Zhao, Li-Ya Zhang, Shu-Xiang Sun, Yan Shi, Yuan-Kai |
author_sort | Zhou, Ping |
collection | PubMed |
description | BACKGROUND: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a promising approach for lymphomas. This study aimed to evaluate the effect of ifosfamide, cisplatin or carboplatin, and etoposide (ICE)-based regimen as a mobilization regimen on relapsed, refractory, or high-risk aggressive lymphoma. METHODS: From June 2001 to May 2013, patients with lymphomas who mobilized by ICE-based regimen for ASCT were analyzed in this retrospective study. The results of the autologous peripheral blood stem cells collection, toxicity, engraftment after ICE-based mobilization regimen were analyzed in this study. Furthermore, risk factors for overall survival (OS) and progression free survival (PFS) were evaluated by univariate analysis. RESULTS: The stem cells were mobilized using ICE-based regimen plus rituximab or ICE-based regimen alone in 12 patients and 54 patients, respectively. The results of stem cell mobilization were excellent. Ninety-seven percentages of the patients had the stem cell collection of at least 2.0 × 10(6) CD34(+) cells/kg and 68% had at least 5 × 10(6) CD34(+) cells/kg. Fifty-eight percentage of the patients experienced Grade 4 neutropenia, 20% developed febrile neutropenia, and only 12% had Grade 4 thrombocytopenia. At a median follow-up of 63.8 months, the 5-year PFS and OS were 64.4% and 75.3%, respectively. CONCLUSION: ICE is a powerful regimen for stem cell mobilization in patients with lymphomas. |
format | Online Article Text |
id | pubmed-4725560 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-47255602016-04-04 Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas Zhou, Ping Liu, Peng Zhou, Sheng-Yu He, Xiao-Hui Han, Xiao-Hong Qin, Yan Yang, Sheng Zhang, Chang-Gong Gui, Lin Yao, Jia-Rui Zhao, Li-Ya Zhang, Shu-Xiang Sun, Yan Shi, Yuan-Kai Chin Med J (Engl) Original Article BACKGROUND: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a promising approach for lymphomas. This study aimed to evaluate the effect of ifosfamide, cisplatin or carboplatin, and etoposide (ICE)-based regimen as a mobilization regimen on relapsed, refractory, or high-risk aggressive lymphoma. METHODS: From June 2001 to May 2013, patients with lymphomas who mobilized by ICE-based regimen for ASCT were analyzed in this retrospective study. The results of the autologous peripheral blood stem cells collection, toxicity, engraftment after ICE-based mobilization regimen were analyzed in this study. Furthermore, risk factors for overall survival (OS) and progression free survival (PFS) were evaluated by univariate analysis. RESULTS: The stem cells were mobilized using ICE-based regimen plus rituximab or ICE-based regimen alone in 12 patients and 54 patients, respectively. The results of stem cell mobilization were excellent. Ninety-seven percentages of the patients had the stem cell collection of at least 2.0 × 10(6) CD34(+) cells/kg and 68% had at least 5 × 10(6) CD34(+) cells/kg. Fifty-eight percentage of the patients experienced Grade 4 neutropenia, 20% developed febrile neutropenia, and only 12% had Grade 4 thrombocytopenia. At a median follow-up of 63.8 months, the 5-year PFS and OS were 64.4% and 75.3%, respectively. CONCLUSION: ICE is a powerful regimen for stem cell mobilization in patients with lymphomas. Medknow Publications & Media Pvt Ltd 2015-09-20 /pmc/articles/PMC4725560/ /pubmed/26365969 http://dx.doi.org/10.4103/0366-6999.164936 Text en Copyright: © 2015 Chinese Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Zhou, Ping Liu, Peng Zhou, Sheng-Yu He, Xiao-Hui Han, Xiao-Hong Qin, Yan Yang, Sheng Zhang, Chang-Gong Gui, Lin Yao, Jia-Rui Zhao, Li-Ya Zhang, Shu-Xiang Sun, Yan Shi, Yuan-Kai Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas |
title | Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas |
title_full | Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas |
title_fullStr | Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas |
title_full_unstemmed | Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas |
title_short | Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas |
title_sort | ifosfamide, cisplatin or carboplatin, and etoposide (ice)-based chemotherapy for mobilization of autologous peripheral blood stem cells in patients with lymphomas |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725560/ https://www.ncbi.nlm.nih.gov/pubmed/26365969 http://dx.doi.org/10.4103/0366-6999.164936 |
work_keys_str_mv | AT zhouping ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas AT liupeng ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas AT zhoushengyu ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas AT hexiaohui ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas AT hanxiaohong ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas AT qinyan ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas AT yangsheng ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas AT zhangchanggong ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas AT guilin ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas AT yaojiarui ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas AT zhaoliya ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas AT zhangshuxiang ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas AT sunyan ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas AT shiyuankai ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas |